Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

NICE deems MSD’s Keytruda cost-effective as first-line lung cancer therapy

pharmatimesJuly 06, 2018

Tag: lung cancer , pembrolizumab

PharmaSources Customer Service